EVEREST data on use of tolvaptan published in JAMA and featured at ACC

PRINCETON, N.J., March 25, 2007-- Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) published in the March 28 issue of the Journal of the American Medical Association (JAMA). These data were presented at the American College of Cardiology's 56th Annual Scientific Sessions (ACC).

The phase 3 EVEREST trial, involving a total of 4,133 ADHF patients, represents three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient care or discharge, whichever came first.

Data from the two short-term studies documented that tolvaptan treatment yielded significantly greater improvements than placebo based on the primary endpoint (study A: p less than 0.001 and study B: p less than 0.001), which was the composite score of changes in patient-assessed global clinical status and changes in body weight at day seven or discharge. Long-term tolvaptan use did not differ from placebo on either of the study's two primary endpoints: deaths from all causes (p equal to 0.68) or from the combined endpoint of cardiovascular (CV) deaths or subsequent hospitalization for worsening HF (p equal to 0.55).

"Tolvaptan exhibited short-term symptomatic benefits in patients hospitalized with worsening heart failure," said investigator Marvin A. Konstam, M.D., chief of the Division of Cardiology at the Tufts- New England

Contact: Debra Kaufmann
Porter Novelli

Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:
TAG: EVEREST data use tolvaptan published JAMA and featured ACC

(Date:10/10/2015)... MI (PRWEB) , ... October 10, 2015 , ... Isabel ... MO. , On the heels of the release of the Institute of Medicine’s ... tools, and their integration with Cerner solutions that assist healthcare providers and consumers to ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... for highly sought after internships at the pre-eminent organization in global health: the ... to eliminating social and health disparities. These internships are a mechanism for WHO ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, according ... of dying in reported home fires in half. As part of Fire Prevention Week, ... property installed and maintained. , Half of home fire deaths result from fires reported ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS ... in Madrid, Spain. Representing both the USA and Sweden in the Speed and Power ... Am Front Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... States, is welcoming individuals from all walks of life to save money on ... set price of $25 per month per medication, individuals and families can receive ...
Breaking Medicine News(10 mins):
(Date:10/9/2015)... October 9, 2015 --> ... has announced its execution of an Intellectual Property & Subsidiary ... Cannabics, Inc. a Delaware Corporation, related party, and a ... --> --> These agreements were ... Company, whereby the Research and Development components shall now ...
(Date:10/9/2015)...  The Centers for Disease Control and Prevention, ... Infectious Diseases, Office of Advanced Molecular Detection (OAMD), ... collaboration to evaluate the performance of Edico Genome,s ... collaboration is to evaluate the utility of the ... infectious disease applications. This collaboration will also focus ...
(Date:10/9/2015)... , Oct. 9, 2015   Lexicon Pharmaceuticals, Inc. ... the TELESTAR Phase 3 clinical study of telotristat etiprate has ... Society annual symposium to be held from October 15-17, in ... interviews with patients who completed the randomized treatment portion of ... in a poster session. --> ...
Breaking Medicine Technology:
Cached News: